Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: Moderating influence of a hallucinatory trait

Frontiers in Pharmacology

Volumn 3 SEP, Issue , 2012, Pages

  Knott, Verner ^a,b,c   Shah, Dhrasti ^a   Millar, Anne ^a   McIntosh, Judy ^a   Fisher, Derek ^d   Blais, Crystal ^b   Ilivitsky, Vadim ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d MOUNT SAINT VINCENT UNIVERSITY   (Canada)

Author keywords

Attention; Mismatch negativity; N methyl d aspartate receptor; Nicotine; Nicotinic acetylcholine receptor; Rapid visual information processing task; Schizophrenia; Sensory memory

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE GUM; NICOTINIC RECEPTOR; PLACEBO;

ARTICLE; ATTENTION; AUDITORY HALLUCINATION; AUDITORY MEMORY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELUSION; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; EVOKED CORTICAL RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MEMORY DISORDER; MISMATCH NEGATIVITY; NEUROMODULATION; NEUROTRANSMISSION; NORMAL HUMAN; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHIZOPHRENIA; TREATMENT DURATION; VISUAL INFORMATION;

EID: 84867124030     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00172     Document Type: Article

References (135)

1. Adell, A., Jimenez-Sanchez, L., LopezGil, X., and Roman, T. (2012). Is the acute NMDA receptor hyopfunction a valid model of schizophrenia? Schizophr. Bull. 38, 9-14.
2. Amitai, N., and Markou, A. (2009). Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl.) 202, 275-286.
3. Andreasen, J., Anderson, K., Neilsen, F., Matheasen, L., and Mirzen, N. (2006). Nicotine and clozapine selectivity reverse a PCP-induced deficit of PPI in BALB/cBy but not MMRI mice: comparison with risperidone. Behav. Brain Res. 167, 118-127.
4. Aracava, Y., Pereira, E., Maelicke, A., and Albuquerque, E. (2005). Memantine blocks alpha7 nicotine acetylcholine receptors more potently than N-methyl-D-aspartate receptors in hippocampal neurons. J. Pharmacol. Exp. Ther. 312, 1195-1205.
5. Baldeweg, T., Klugman, A., Gruzwliwe, J., and Hirsch, S. (2004). Mismatch negativity and cognitive impairment in schizophrenia. Schizophr. Res. 69, 203-217.
6. Baldeweg, T., Wong, D., and Stephan, K. (2006). Nicotinic modulation of hourly auditory sensory memory: evidence from mismatch negativity potentials. Int. J. Psychophysiol. 59, 49-58.
7. Barch, D., Moore, H., Nee, D., Manoach, D., and Luck, S. (2012). CNTRCS imaging biomarkers selection: working memory. Schizophr. Bull. 38, 43-52.
8. Barr, R., Culhane, M., Jubelt, L., Mufti, R., Dyer, M., Weiss, A., Deckersbach, T., Kelly, J., Freudenreich, O., Goff, D., and Evens, A. (2008). The affects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharma- cology 3, 480-490.
9. Bell, M. (1992). Bell Object Relations and Reality Testing Inventory. Los Angeles, CA: Western Psychological Services.
10. Bell, M., Billington, R., and Becker, B. (1985). Scale for the assessment of reality testing: reliability, validity, and factorial invariance. J. Consult. Clin. Psychol. 553, 506-511.
11. Bieszczad, K., Kant, R., Constantinescu, C., Pandey, S., Kauai, H., Metherate, R., Weinberger, N., and Mukherjee, J. (2012). Nicotinic acetylcholine receptors in rat forebrain that bind 18F-Nifene: relating PET imagining, autoradiography, and behaviour. Synapse 66, 418-434.
12. Breese, C. R., Lee, M. J., Adams, C. E., Sullivan, B., Logel, J., Gillen, K. M., Marks, M. J., Collins, A. C., and Leonard, S. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharma- cology 23, 351-354.
13. D'Souza, M., and Markou, D. (2011). Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 62, 1564-1573.
14. Daalman, K., Boks, M., Dierderen, K., Weijer, A., Blom, J., Kahn, R., and Sommer, I. (2011). The same or different? A phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. J. Clin. Psychiatry 72, 320-3250.
15. Dulude, L., Labelle, A., and Knott, V. (2010). Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J. Clin. Psychopharmacol. 30, 541-548.
16. Dunbar, G., Boeijinga, P. H., Demazières, A., Cisterni, C., Kuchibhatla, R., Wesnes, K., and Luthringer, R. (2007). Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl.) 191, 919-929.
17. Edeline, J. (2003). The thalamo-cortical auditory receptive fields: regulation by the states of vigilance, learning and the neuromodulatory systems. Exp. Brain Res. 153, 554-572.
18. Eleväg, B., and Goldberg, T. (2000). Cognitive impairment in schizophrenia as the core of the disorder. Crit. Rev. Neurobiol. 14, 1-21.
19. Engeland, C., Mahoney, C., Mohr, E., Ilivitsky, V., and Knott, V. J. (2002). Acute nicotine effects on auditory sensory memory in tacrine treated and nontreated patients with Alzheimer's disease: an event-related potential study. Pharmacol. Biochem. Behav. 72, 457-464.
20. Evans, D., and Drobes, D. (2009). Nicotine self-medication of cognitiveattentional processing. Addict. Biol. 14, 32-42.
21. Fisher, D., Grant, B., Smith, D., Borracci, G., Labelle, A., and Knott, V. (2011). Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multifeature paradigm. Int. J. Psychophys- iol. 81, 245-251.
22. Fisher, D., Labelle, A., and Knott, V. (2008). Auditory hallucinations and the mismatch negativity: processing speech and non-speech sounds in schizophrenia. Int. J. Psychophysiol. 70, 3-15.
23. Fisher, D., Labelle, A., and Knott, V. (2012a). Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr. Res. 139, 237-245.
24. Fisher, D., Smith, D., Labelle, A., and Knott, V. (2012b). Auditory mismatch negativity (MMN) in acutely ill and stable schizophrenia patients with auditory hallucinations. Clin. Neurophysiol. (in press).
25. Fisher, D., Scott, T., Shah, D., Prise, S., Thompson,M.,and Knott,V. (2010). Light up and see: enhancement of the visual mismatch negativity (vMMN) by nicotine. Brain Res. 1313, 162-171.
26. Flores-Hernandez, J., Saigadog, H., De La Rosa, V., Avita-Ruiz, T., TorresRamiresz, O., Lopez-Lopez, G., and Atzori,M. (2009). Cholinergic direct inhibition of N-methyl-D-aspartate receptor-mediated currents in the rat neocortex. Synapse 63, 308-318.
27. Ford,J. M.,Roach,B. J.,Jorgensen,K.W., Turner, J. A., Brown, G. G., Notestine, R., Bischoff-Grethe, A., Greve, D., Wible, C., Lauriello, J., Belger, A., Mueller,B. A., Calhoun,V.,Preda,A. Keator, D., O'Leary, D. S., Lim, K. O., Glover, G., Potkin, S. G., FBIRN, and Mathalon,D. H. (2009). Tuning in to the voices: a multisite FMRI study of auditory hallucinations. Schizophr. Bull. 35, 58-66.
28. Fu, Y., Matta, S., Gao, W., Brower, V., and Sharp, B. (2000). Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral area. J. Phar- macol. Exp. Ther. 294, 458-465.
29. Green, M. (2007). Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu. Rev. Clin. Psychol. 3, 159-180.
30. Gunduz-Bruce, H., Reinhart, R., Roach, B., Gueorguieva, R., Oliver, S., D'Souza, D., Ford, J., Krystal, J., and Mathalon, D. (2012). Glutamatergic modulation of auditory information processing in the human brain. Biol. Psychiatry 71, 969-977.
31. Harkrider, D., and Hedrick, M. (2005). Acute effects of nicotine on auditory gating in smokers and non-smokers. Hear. Res. 202, 114-128.
32. Harris, J., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B., Zerbe, G., and Freedman, R. (2004). Effects of nicotine on cognitive deficits in schizophrenia. Neuropsy- chopharmacology 29, 1378-1385.
33. Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T., and GouzoulesMayfrank, E. (2008). Mismatch negativity generators in the human 5HT2A agonist and NMDA model of psychosis. Psychopharmacology (Berl.) 199, 77-88.
34. Heinrichs, R. W. (2005). The primacy of cognition in schizophrenia. Am. Psychol. 60, 229-242.
35. Heishman, S. (1999). Behavioural and cognitive effects of nicotine: relationship to nicotine addiction. Nico- tineTob. Res. 1(Suppl. 2),S143-S147. Heishman, S., Kleykamp, B., and Singleton, E. (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl.) 210, 453-469.
36. Hilti, C., Hilti, L., Heinemann, D., Robbins, T., Seifritz, E., and CattapanLudewig, K. (2010). Impaired performance in the rapid visual information task (RVIP) could be an endophenotype of schizophrenia. Psychiatry Res. 177, 60-64.
37. Hirayasu, Y., Potts, G., O'Donnell, B., Kwon, J., Arakaki, H., Akdag, S., Levitt,J.,Shenton,M.,and McCarley, R. (1998). Auditory mismatch negativity in schizophrenia: topographic evaluation with a high density recording montage. Am. J. Psychiatry 155, 1281-1284.
38. Holcomb, H., Ritzl, F., Medoffi, D., Nevitt, J., Gordon, B., and Tamminga, C. (1995). Tone discrimination performance in schizophrenia patients and normal volunteers: impact of stimulus presentation levels and frequency differences. Psychi- atry Res. 57, 75-82.
39. Hong, L., Schroeder, M., Ross, T., Bucholz, B., Salmeron, B., Wonodi, I., Thaker, G. K., and Stein, E. A. (2011). Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr. Res. 34, 416-425.
40. Hugdahl, K., Lobery, E.-M., Specht, K., Steen, V., van Wageningen, H., and Jorgensen, H. (2008). Auditory hallucinations in schizophrenia: the role of cognitive, brain structural and genetic disturbances in the left temporal lobe.Front. Hum.Neurosci. 1:6. doi:10.3389/neuro.09.006.2007 Hukkanen, J., Jacob, P. 3rd, and Benowaitz, N. (2005). Metabolism and deposition kinetics of nicotine. Pharmacol. Rev. 37, 79-115.
41. Inami, R., Kirino, E., Inoue, R., Suzuki, T., and Arai, H. (2007). Nicotine effects on mismatch negativity in schizophrenia patients. Neuropsy- chobiology 36, 64-72.
42. Inauri, R., Kirino, E., Inoue, R., and Arai, H. (2005). Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol. Biochem. Behav. 80, 453-461.
43. Intskirveli, I., and Metherate, R. (2012). Nicotinic neuromodulation in auditory cortex requires XNAPK activation in thalamocortical and intracortical circuits. J. Neurophysiol. 107, 2782-2793.
44. Irnaten, M., Wang, J., Venkatesan, P., Evans, C. K., Chang, K. S., Andresen, M. C., and Mendelowitz, D. (2002). Ketamine inhibits presynaptic and postsynaptic excitation of cardiac parasympathetic neuron in nucleus ambiguous. Anesthesiology 96, 667-674.
45. Jackson, A., Nesic, J., Groombridge, C., Clowry, O., Rusted, J., and Duka, J. (2009). Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 34, 257-265.
46. Jacobsen, L. K., D'Souza, D. C., Mencl, W. E., Pugh, K. R., Skudlarski, P., and Krystal, J. H. (2004). Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatry 55, 850-858.
47. Javitt, D. (2010). Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci. 47, 4-16.
48. Javitt, D., Doneshka, P., Grochowski, D., and Ritter, W. (1995). Impaired mismatch negativity generation reflects widespread dysfunction of working memory on schizophrenia. Arch. Gen. Psychiatry 52, 550-558.
49. Javitt, D., Schroeder, C., Steinschneider, M., Arizzo, J., and Vaughan, H. (1992). Demonstration of mismatch negativity in the monkey. Electroencephalogr. Clin. Neurophys- iol. 83, 87-90.
50. Javitt, D., Steinschneider, M., Schroeder, C.,and Arezzo,J. (1996). Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 93, 11962-11967.
51. Javitt, D., Steinschneider, M., Schroeder, C., Vaughan, H., and Arezzo, J. (1994). Detection of stimulus deviance within primate auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res. 667, 192-200.
52. Kantrowitz, J., and Javitt, D. (2010). Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 4, 189-200.
53. Kasai, K., Yamada, H., Kamio, S., Nakagome, K., Iwanami, A., Fukuda, M., Yumoto, M., Itoh, K., Koshida, I., Abe,O.,and Kato,N.(2002).Dohigh or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenia subjects? An EEG and MEG study. Clin. Neurophysiol. 113, 141-150.
54. Kayser, J., Tenke, C., Kroppmann, C., Alschuler, D., Fekri, S., Gil, R., Jarskog, L., Harkavey-Friedman, J., and Buder, G. (2012). Auditory hallucinations in schizophrenia are associated with neurophysiological deficits in early visual processing. Presented at 67th Annual Meeting of the Society for Biological Psychiatry, Philadelphia.
55. Kharazia, V., and Weinberg, R. (1994). Glutamate in thalamic fibres terminating in layer IV of primary sensory cortex. J. Neurosci. 14, 6021-6032.
56. Knott, V. (1989). "Brain event-related potentials in smoking performance research," in Smoking and Human Behaviour, eds T. Ney and A. Gale (Chichester: John Wiley & Sons), 93-114.
57. Knott, V., Bosman, M., Mahoney, C., Ilivitsky, V., and Quirt, K. (1999). Transdermal nicotine: single dose effects on mood, EEG, performance and event-related potentials. Phar- macol. Biochem. Behav. 63, 253-261.
58. Knott, V., Hooper, C., Lusk-Mikkelsen, S., and Kerr, C. (1995). "Aspects of brain electric event-related potential (ERP) topography related to cigarette smoking, attention, cognition and psychopathology," in Brain Imaging of Nicotine and Tobacco Smoking,ed. E. Domino (Ann Arbor, MI: NPP Books), 191-221.
59. Knott, V., McIntosh, J., Millar, A., Fisher, D., Villeneuve, C., Ilivitsky, V., and Horn, E. (2006). Nicotine and smoker status moderate brain electric and mood activation induced by ketamine and Nmethyl-D-aspartate (NMDA) antagonist. Pharmacol. Biochem. Behav. 85, 228-242
60. Knott, V., Millar, A., McIntosh, J., Shah, D., Fisher, D., Blais, C., Ilivitsky, V., and Horn, E. (2011). Separate and combined effects of low dose ketamine and nicotine in behavioural and neural correlates of sustained attention. Biol. Psychol. 88, 83-93.
61. Koychev, I., Barkus, E., Ettinger, V., Killcross, S., Roiser, J., Wilkinson, L., and Deakin, B. (2011). Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. J. Psychopharmacol. (Oxford) 25, 1207-1225.
62. Kreitschmann-Andermahr, I., Rosburg, T., Demme, U., Gaser, E., Nowak, H., and Javer, H. (2001). Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res. Cogn. Brain Res. 12, 109-116.
63. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner,J. D.,Heninger,G. R.,Bowers,M. B. Jr.,and Charney,D. S. (1994). Subanesthetic effects of noncompetitive NMDA receptor antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses.Arch. Gen. Psychi- atry 51, 199-214.
64. Krystal, J. H., Perry, E. B. Jr., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., and D'Souza, D. C. (2005a). Comparative and interaction human psychopharmacologic effects of ketamine and amphetamine. Arch. Gen. Psychiatry 62, 985-995.
65. Krystal, J. H., Abi-Saab, W., Perry, E., D'Souza,D. C.,Liu,N.,Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., and Breier, A. (2005b). Preliminary evidence of attenuation of the disruptive effects of NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist,24354340,in healthy human subjects. Psychopharmacology (Berl.) 129, 303-309.
66. Kuhn, S., and Gallinat, J. (2010). Quantitative meta-analyses on state and trait aspects of auditory verbal hallucinations in schizophrenia. Schiz- ophr .Bull. 126, 20-27.
67. Kumari, V., and Postman, P. (2005). Nicotine use in schizophrenia: the self-medication hypotheses. Neu- rosci. Biobehav. Rev. 29, 1021-1024.
68. Lambe, E., Picciotto, M., and Aghajanian, G. (2003). Nicotine induces glutamate release from thalamacortical terminals in prefrontal cortex. Neuropsychopharmacology 28, 216-225.
69. Large, C. (2007). Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychophar- macol. (Oxford) 21, 283-301.
70. Lawrence, N., Ross, T., and Stein, E. (2002). Cognitive mechanisms of nicotine on visual attention. Neuron 36, 539-548
71. Levin, E., and Rezvani, A. (2006). "Nicotine-antipsychotic drug interactions and cognitive function," in Neurotransmitter Interactions and Cognitive Functions, ed. E. Levin (Berlin: Birkhauser Veclas), 185-205.
72. Levin, E., Rizabis, Y., Rezvani, A., Caldwell, D., Petro, A., and Getachew, B. (2005). Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding. Brain Res. 1041, 132-142
73. Levin, E., Sledge, D., Varvah, A., and Addy, M. (2003). Ventral hippocampal NMDA blockade and nicotinic effects of memory function. Brain Res. Bull. 61, 489-495.
74. Liang, K., Poytress, B., Weinberger, N., and Metherate, R. (2008). Nicotinic modulation of tone-evoked responses in auditory cortex reflects the strength of prior auditory learning. Neurobiol. Learn. Mem. 90, 138-146.
75. Lin, C.-H., Lane, H. Y., and Tzai, G. (2012). Glutamate signaling in the pathophysiology of schizophrenia. Pharmacol. Biochem. Behav. 100, 665-677.
76. Macmillan, M., and Creelman, C. (1997). d' plus: A program to calculate accuracy and bias measures from detection and discrimination data. Spat. Vis. 11, 141-143.
77. Malhotra, A., Pinals, D., Weingartner, H., Sirocco, K., Messar, C., and Pickar, D. (1996). NMDA receptor hypofunction and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacol- ogy 14, 301-307.
78. Mansvelder, H., van Aerde, K., Covey, J. J., and Brussaard, A. B. (2006). Nicotine modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl.) 184, 292-305.
79. Marsman, A., van den Heuvel, M., Klomp, D., Kahn, R., Lujten, P., and Hulsholf Pol, H. (2011). Glutamate in schizophrenia: a focused review and meta-analysis of H-MRS studies. Schizophr. Bull. [Epub ahead of print].
80. Martin, L., Davalos, D., and Kisley, M. (2009). Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob. Res. 11, 698-706.
81. Mathew, V., Gruzelier, J., and Liddle, P. (1993). Lateral asymmetries in auditory acuity distinguish hallucinating from nonhallucinating schizophrenic patients. Psychiatry Res. 46, 127-138.
82. Metherate, R. (2004). Nicotinic acetylcholine receptors in sensory cortex. Learn. Mem. 11, 50-59.
83. Metherate, R., and Hsieh, C. (2003). Regulation of glutamate synapses by nicotinic acetylcholine receptors in auditory cortex. Neurobiol. Learn. Mem. 80, 285-290.
84. Morley, B., and Happe, H. (2000). Cholingergic receptors: dual roles in transduction and plasticity. Hear. Res. 147, 104-112.
85. Naatanen, R., and Kahkonen, S. (2009). Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int. J. Neuropsychopharma- col. 12, 125-135.
86. Naatanen, R., Kujala, T., and Winkler, J. (2011). Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses. Psychophysiology 48, 4-22.
87. Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V., Selke, G., Melson, A. K., Hershey, T., Craft, S., and Olney, J. W. (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20, 106-118.
88. Newhouse, P., Potter, A., and Singh, A. (2004). Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. 4, 36-46.
89. Nurnberger, J. I. Jr., Blehar, M. C., Kaufmann, C. A., York-Cooler, C., Simpson, S. G., Harkavy-Friedman, J., Severe, J. B., Malaspina, D., and Reich, T. (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry 51, 848-859.
90. Ochoa, E., and Lasalde-Dominicci, J. (2007). Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell. Mol. Neurobiol. 27, 609-639.
91. Olincy,A.,and Stevens,K. (2007). Treating schizophrenia symptoms with an a7 nicotinic agonist, from mice to men. Biochem. Pharmacol. 74, 1192-1201.
92. Oranje, B., van Berckel, B., Kemmer, C., van Ree, J., Kahn, R., and Verbaten, M. (2000). The effects of subanaesthetic dose of ketamine on human selective attention. Neu- ropsychopharmacology 3, 293-302.
93. Overall, J., and Gorham, D. (1962). The brief psychiatric rating scale. Psychol. Rep. 10, 799-812.
94. Plazas, P., Savino, J., Kracun, S., GomezCasati, M., Katz, E., Parsons, C., Millar, N., and Elgoyhen, A. (2007). Inhibition of the alpha9 alpha10 nicotinic cholinergic receptors neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur. J. Pharmacol. 566, 11-19.
95. Pritchard, W., Sokhadze, E., and Houlihan, M. (2004). Effects of nicotine and smoking on event-related potentials: a review. Nicotine Tob. Res. 6, 961-984.
96. Quarta, D., Naylor, C., Morris, N., Patel, S., Genn, R., and Stolermay, I. (2007). Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine. Neuropharmacology 53, 421-430.
97. Quednow, B., Brinkmeyer, J., Mobascher, A., Nothnagel, M., Musso, F., Grunder, G., Savary, N., Petrovsky, N., Frommann, I., Lennertz, L., Spreckelmeyer, K. N., Wienker, T. F., Dahmen, N., Thuerauf, N., Clepce, M., Kiefer, F., Majic, T., Mössner, R., Maier, W., Gallinat, J., Diaz-Lacava, A., Toliat, M. R., Thiele, H., Nürnberg, P., Wagner, M., and Winterer, G. (2012). Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc.Natl.Acad.Sci.U.S.A. 109, 6271-6276.
98. Rabinowicz, E., Silipo, G., Goldman, R., and Javitt, D. (2000). Auditory sensory dysfunction in schizophrenia: imprecision or distractibility? Arch. Gen. Psychiatry 57, 1149-1155.
99. Radcliffe, K., Fisher, J., Gray, R., and Dani, J. (1999). Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann. N. Y. Acad. Sci. 868, 591-510
100. Radek, R., Kohlhaas, K., Rueter, L., and Mohler, E. (2010). Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr. Pharm. Des. 16, 304-322.
101. Rasmussen, B., Perry, D., O'Neil, J., Manaye, K., and Tizubis, Y. (2008). Effects of nicotine on sensorimotor gating impairment induced by long term treatment with neurotoxic NMDA antagonism. Neurotox. Res. 13, 151-161.
102. Rezvani, A., Kholderbarin, E., Dawson, E., and Levin, E. (2008). Nicotine and clozapine effects on attentional performance by the NMDA antagonist dizocilpine in female rats. Int. J. Neuropsychopharmacol. 11, 63-70.
103. Rezvani, A., and Levin, E. (2003). Nicotinic-glutamatergic interactions of attentional performance on an apparent visual signal detection task in female rats. Eur. J. Pharmacol. 465, 83-90.
104. Rinne, T., Alho, K., Ilmonlemi, R., Virtanen, J., and Naatanen, R. (2000). Separate time behaviours of the temporal and frontal mismatch negativity sources. Neuroimage 12, 14-19.
105. Roser, P., Hauzsfeiter, I., Chong, H.-J., Maler, C., Kawohl,W., Norra, C.,and Juckel, G. (2011). Inhibition of cerebral type I cannabinoids receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology (Berl.) 218, 611-620.
106. Schall, U., Catts, S., Chaturvedi, S., Liebert, B., Redenbach, J., Karayandis, F., and Ward, P. (1998). The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and extent-related potential measures. Int. J. Neuropsy- chopharmacol. 1, 19-29.
107. Schilström, B., Fagerquist, M. V., Zhang, X., Hertel, P., Panagis, G., Nomikos, G. G., and Svensson, T. H. (2000). Putative role of presynoptic alpha 7 nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38, 375-383.
108. Schmidt, A., Bachmann, R., Kometer, M., Csmor, P., Stephan, K., Seifritz, E., and Voklenweider, F. (2012a). Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsycho pharmacology 37, 865-875.
109. Schmidt, A., Diaconescu, A., Kometer, M., Friston, L., Stephan, K., and Vollenweider, F. (2012b). Modeling ketamine effects on synaptic plasticity during the mismatch negativity. Cereb. Cortex [Epub ahead of print].
110. Sehatpour, L., Higgins, B., Foxe, J., and Javitt,D. (2010). Sensory deficits and distributed hierarchical dysfunction in schizophrenia. Am. J. Psychiatry 167, 818-827.
111. Smith, R., Warner-Cohen, J., Matute, M., Butler, E., Kelly, E., Vaidhyanathaswamy, S., and Khan, A. (2006). Effects of nicotine spray on cognitive function in schizophrenia. Neuropsychopharmacology 31, 637-643.
112. Soto, G., Kopell, N., and Sen, K. (2006). Network architecture, receptive fields, and neuromodulation: computational and functional implications of cholinergic modulation in primary auditory cortex. J. Neurophysiol. 96, 2972-2983.
113. Spieleway, C., and Markov, A. (2004). Strain-specificity in nicotine attraction of phencyclidine-induced disruption of prepulse inhibition in mice and relevance to smoking in schizophrenia patients. Behav. Genet. 34, 343-354.
114. Strous, R., Grochowski, S., Cowan, N., and Javitt, D. (1995). Dysfunctional encoding of auditory information in schizophrenia. Schiozphr. Res. 15, 135.
115. Tassonyi, E., Charpantier, E., Muller, D., Dumont, L., and Bertrand, D. (2002). The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res. Bull. 57, 133-150.
116. Tcheremissine, O., Castro, M. A., and Gardner, D. (2012). Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community health researchers. Expert Opin. Investig. Drugs 21, 7-14.
117. Terry, A., Rishbrough, V., Buccafusco, J., and Menzush, F. (2002). Effects of (+/-)-4-[[2(1-methyl-2-pyrrolidinylethyl]
118. thio]phenol hydrochloride (SIB1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J. Pharmacol. Exp. Ther. 301, 284-292.
119. Thompson, D., and Winsaver, P. (1986). Nicotine canattenuatethedisruptive effects of phencyclidine on repeated acquisition in monkeys. Pharmacol. Biochem. Behav. 25, 185-190.
120. Thonnesen, H., Zryagintsev, M., Harke, K., Boers, F., Danmers, J., Norra, C., and Mathiak, K. (2008). Optimized mismatch negativity paradigm effects deficits in schizophrenia patients: a combined EEG and MEG study. Biol. Psychol. 77, 205-216.
121. Tikhonravov, D., Neuvonen, T., Pertovaara, A., Savioja, K., Ruusuvirta, T., Naatanen,R.,and Carlson,S. (2008). Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res. 1203, 97-102.
122. Tikhonravov, D., Neuvonen, T., Pertovgara, A., Savioja, K., Rousuvirta, T., Naatanen, R., and Carklson, S. (2010). Dose-related effects of Memantine on a mismatch negativity-like response in anesthetized rats. Neuroscience 167, 1175-1182.
123. Timofeeva, O., and Levin, E. (2011). Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience 195, 21-36.
124. Umbricht, D., Javitt, D., Novak, G., Bates, J., Pollack, S., Lieberman, J., and Kane, J. (1998). Effects of clozapine and auditory event-related potentials in schizophrenia. Biol. Psychiatry 44, 716-725.
125. Umbricht, D., Koller, R., Vollenweider, F., and Schmid, L. (2002). Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51, 400-406.
126. Umbricht,D.,and Krljes,S. (2005). Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 76, 1-23.
127. Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., and Javitt, D. C. (2000). Ketamineinduced deficits in auditory and visual context-dependent processing in healthy volunteers. Implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 37, 1139-1147.
128. Umbricht, D., and Vollenweider, F. (1999). Effects of the NMDA antagonists and 5-HT2A agonists on generation of MMN in human volunteers [abstract]. Biol. Psychiatry 45, 51S-52S.
129. Urban, A., Kremlacek, J., and Libiger, J. (2007). Mismatch negativity in patients with schizophrenia. Acta Medica Cordoba 50, 23-28.
130. Waters, F., Allen, P., Aleman, A., Fernyhough, C., Woodward, T., Badcock, J., Barkhaus, E., Johns, L., Varese, F., Menon, M., Vercammen, A., and Lavoi, F. (2012). Auditory hallucinations in schizophrenia and nonschizophrenic populations: a review and integrated model of cognitive mechanisms. Schizophr. Bull. 38, 683-693.
131. Wesnes, K., and Warburton, D. (1984). Effects of scopolamine and nicotine on human information processing performance. Psychopharmacol. 82, 147-150.
132. Wexler, B., Stevens, A., Bowers, A., Sernyak, M., and Goldman-Rakic, P. (1998). Word and tone working memory deficits in schizophrenia. Arch. Gen. Psychiatry 55,1093-1096.
133. Winterer, G. (2010). Why do patients with schizophrenia smoke? Curr. Opin. Psychiatry 23, 112-119.
134. Wynn, J., Sugar, C., Horan, W., Kem, R., and Green, M. (2010). Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol. Psychiatry 67, 940-947
135. Youn, T., Park, H.-J., Kim, J.-J., Kim, M., and Kwon, J. (2003). Altered hemispheric asymmetry and positive symptoms in schizophrenia: equivalent current dipole of auditory mismatch negativity. Schizophr. Res. 59, 253-260.